ストックスクリーナーアプリを入手
0.411
25.42%
0.0833
前日終値:
$0.3277
開ける：
$0.4341
24時間の取引高:
109.48M
Relative Volume:
6.02
時価総額：
$78.48M
収益：
$4.71M
当期純損益:
$-58.01M
株価収益率:
-0.4991
EPS:
-0.8234
ネットキャッシュフロー:
$-46.68M
1週間 パフォーマンス:
-14.02%
1か月 パフォーマンス:
-51.01%
6か月 パフォーマンス:
-62.29%
1年 パフォーマンス:
-66.59%
1日の値動き範囲:
$0.388
$0.4525
1週間の範囲:
$0.303
$0.4802
52週間の値動き範囲:
$0.303
$1.6293
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Compare LUCD vs ABT, MDT, SYK, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
0.411 | 78.48M | 4.71M | -58.01M | -46.68M | -0.8234 |
ABT
Abbott Laboratories
|
103.70 | 179.44B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
95.41 | 122.04B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
307.15 | 117.81B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.69 | 66.22B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.07 | 51.34B | 6.30B | 1.07B | 1.09B | 1.8406 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-12-27 | 開始されました | Ascendiant Capital Markets | Buy |
| 2021-11-08 | 開始されました | BTIG Research | Buy |
| 2021-11-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-11-08 | 開始されました | Needham | Buy |
Lucid Diagnostics Inc (LUCD) 最新ニュース
Oil Above $100 Puts Penny Stocks in Focus - GlobeNewswire Inc.
Form 8K Lucid Diagnostics Inc For: 22 October By Investing.com - Investing.com India
Lucid Diagnostics raises $15 million through Series C preferred stock sale - Investing.com UK
Medicare has begun paying $1,938.01 for each of Lucid’s esophageal DNA tests. - Stock Titan
Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing - PR Newswire
Lucid Diagnostics Receives Nasdaq Notice for Sub-$1 Bid Price, Faces Compliance Deadline - Kalkine Media
Lucid Diagnostics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways - Finansavisen
A new billing code was approved for a tool that collects esophageal cells. Medicare payment remains pending. - Stock Titan
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways - Yahoo Finance
Form 8K Lucid Diagnostics Inc For: 22 September By Investing.com - Investing.com Nigeria
Ascendiant Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Raises Target Price to $9.5 - Moomoo
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026 - Eastern Progress
Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript - AOL.com
Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript - The Globe and Mail
Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript - The Globe and Mail
Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says - Sahm
Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says - Benzinga
LUCD Q1 2026 Earnings: EPS Misses by 100.7% as Commercialization Costs MountROIC Trend Report - vinanet.vn
PAVmed Q2 2026 slides: loss narrows as device programs advance By Investing.com - Investing.com Nigeria
PAVmed Q2 2026 slides: loss narrows as cash position weakens By Investing.com - Investing.com Nigeria
Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth - MarketBeat
Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth - Yahoo Finance
PAVmed Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
PAVmed Q2 2026 slides: loss narrows as cash position weakens By Investing.com - Investing.com India
Lucid Diagnostics (LUCD) Rises 1.97% as Shares Hold Above Critical Support at $0.93SMA Signal - dars.gov.et
Lucid Diagnostics (LUCD) Rises 1.97% as Shares Hold Above Critical Support at $0.93Imbalance Zone - vinanet.vn
PAVmed Q2 2026 slides: loss narrows as device programs advance By Investing.com - Investing.com Australia
PAVmed Q2 2026 slides: loss narrows as cash position weakens - Investing.com
PAVmed Q2 revenue jumps to $33k; $30m warrants issued - scanx.trade
Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip - Investing.com South Africa
PAVmed Q2 2026 slides: loss narrows as device programs advance - Investing.com
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - Yahoo Finance
Lucid Diagnostics (LUCD) Earnings Call zu Q2 2026: Umsatz steigt um 17 %, Concert-Kostendeckung macht Fortschritte - TradingKey
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - Finansavisen
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
Lucid Diagnostics earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Lucid Diagnostics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LUCD) 2026-08-13 - Seeking Alpha
Lucid Diagnostics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
LUCD Looks 16.3% Overvalued on GF Value™ - GuruFocus
Lucid Diagnostics (LUCD) Slips 1.98% to $0.96 as Shares Hover Above Key SupportRunaway Gap - dars.gov.et
Lucid Diagnostics (LUCD) Slips 1.98% to $0.96 as Shares Hover Above Key SupportUnusual Put Volume - vinanet.vn
Lucid Diagnostics Inc (NASDAQ: LUCD) Share Price, LUCD Stock News, LUCD Share Price & Updates - Kalkine
Financial Report LiveLucid Diagnostics Inc. (LUCD.US) Q2 2026 Earnings Conference Call - Longbridge
Lucid Diagnostics Q2 Earnings Call Highlights - MarketBeat
Lucid Diagnostics Q2 Earnings Call Highlights - Yahoo Finance
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com South Africa
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com Nigeria
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com Australia
Needham reiterates Buy on Lucid Diagnostics stock, $3 target - Investing.com
Lucid Diagnostics Inc (LUCD) 財務データ
収益
当期純利益
現金流量
EPS
2.66%
0.83%
大文字化:
|
ボリューム (24 時間):